Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
SKP-1041 is a new formulation of a marketed sleeping agent called zaleplon. Zaleplon is
currently available as Sonata as well as several generic formulations. Sonata and its
generics induce sleep soon after ingestion. SKP-1041, however, is a formulation that is
designed to become active 2-3 hours after ingestion. It is intended for use in people who
have no trouble falling to sleep but who often awaken in the middle of the night. This trial
will determine the best dose to prevent those awakenings.